University of Connecticut

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Connecticut sits in the top decile of US sponsors by registered trial count (#228 of 15,742 sponsors by registered trial count).

107 total trials 12 currently recruiting 83 completed early-phase tilt top decile by trial count

University of Connecticut: 107 sponsored US clinical trials, 12 recruiting.

University of Connecticut sponsors 107 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 83 completed. 2 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 6 trials.

Top-decile sponsor footprint

University of Connecticut ranks in the top decile of sponsors by registered trial count (#228 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

B 81/100

83 of 86 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (96.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

107 total, page 3 of 3

COMPLETED NA

Breastfeeding Education and Support Trial for Obese Women (BESTOW)

NCT01338727
COMPLETED NA

Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users

NCT01741350
COMPLETED Phase 2

Improving Treatment Adherence in HIV-Infected Individuals

NCT00247611
COMPLETED Phase 2

HIV Prevention Intervention for People Living With HIV/AIDS

NCT01061021
COMPLETED Phase 4

The Use of GnRH Agonist Trigger in the Prevention of OHSS

NCT00349258
TERMINATED NA

Haloperidol vs. Risperidone in the Treatment of Aggression in Psychotic Inmates

NCT00203775
COMPLETED Phase 1

Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase

NCT00027144
← Previous Page 3 of 3

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 3
Phase 4 2

Therapeutic Areas

Obesity 6
Hyperthermia 5
Hypothermia 2
Cardiovascular Disease 2
HIV Infections 2
Hypertension 2
Weight Loss 2
HIV 2
Opioid Use Disorder 2
Heat Intolerance 1

What is open in the University of Connecticut pipeline

12 recruiting of 107 indexed (11% open); 83 completed (78%).

Phase mix: 2 late (III/IV) vs 12 early (I/II) (early-phase heavy).

Top condition: Obesity (6 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Connecticut: open-pipeline peers nationwide

Peers matched on 107 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

University of Connecticut sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200 5%10%15%20% Total trials Recruiting share University of ConnecticutGeisinger ClinicSt. Louis UniversityNemours Children's ClinicAugusta UniversityAstellas Pharma Global DevelopmentADC Therapeutics S.A.Adrian VellaAIDS Malignancy Consortium
University of Connecticut sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Connecticut sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 107 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Connecticut page

107 registered trials is a research-attention snapshot, not an endorsement of University of Connecticut or any single study.

  • 12 of University of Connecticut's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of Connecticut studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Connecticut pipeline card: 107 registered trials from official public datasets.Report a data error.